Efficacy of chemotherapy for malignant pleural mesothelioma according to histology in a real-world cohort

Abstract CheckMate 743 trial demonstrated survival benefit of immunotherapy in first line in MPM with some differences in the efficacy of chemotherapy according to histology. The objective of this study is to characterize the impact of chemotherapy according to histology in patients diagnosed with M...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Susana Cedres, Juan-David Assaf, Patricia Iranzo, Ana Callejo, Nuria Pardo, Alejandro Navarro, Alex Martinez-Marti, David Marmolejo, Alejandra Rezqallah, Caterina Carbonell, Joan Frigola, Ramon Amat, Anna Pedrola, Rodrigo Dienstmann, Enriqueta Felip
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/dda7bac31e5741c2aadbfeb55a39dc46
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:dda7bac31e5741c2aadbfeb55a39dc46
record_format	dspace
spelling	oai:doaj.org-article:dda7bac31e5741c2aadbfeb55a39dc462021-11-08T10:48:34ZEfficacy of chemotherapy for malignant pleural mesothelioma according to histology in a real-world cohort10.1038/s41598-021-00831-42045-2322https://doaj.org/article/dda7bac31e5741c2aadbfeb55a39dc462021-11-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-00831-4https://doaj.org/toc/2045-2322Abstract CheckMate 743 trial demonstrated survival benefit of immunotherapy in first line in MPM with some differences in the efficacy of chemotherapy according to histology. The objective of this study is to characterize the impact of chemotherapy according to histology in patients diagnosed with MPM at our institution. Clinical records of all MPM patients diagnosed at Vall d’Hebron University Hospital between November 2002 and April 2020 were reviewed. Associations between clinical variables and outcomes were assessed with Cox regression models. Survival data were calculated by the Kaplan–Meier method. 189 patients were included with 76% of tumors classified as epithelioid subtype. First line chemotherapy was offered to 85% of patients. Median survival in overall population was 21.3 months (95% CI 17.2–24.3). We found that patients with epithelioid tumors had better overall survival (OS) and progression free survival (PFS). Median OS of epithelioid patients treated with first line chemotherapy was 26.7 months versus 15.0 months in non-epithelioid patients (HR 2.25 CI 95% 1.4–3.4; p < 0.001). Median PFS for patients with epithelioid tumors treated with chemotherapy was 4.8 months versus 3.6 months in non-epithelioid (HR 1.5 CI 95% 1.0–2.3; p = 0.03). The improvement of outcomes in patients with epithelioid histology was detected in patients treated with cisplatin or carboplatin. Histology was not a predictive factor for the platinum agent sensitivity (p of interaction PFS = 0.09, p of interaction OS = 0.65). In our series, patients with non-epithelioid tumors presented worse prognosis. Although epithelioid tumors exposed to cisplatin had higher PFS, histology was not a clear predictor of chemotherapy efficacy.Susana CedresJuan-David AssafPatricia IranzoAna CallejoNuria PardoAlejandro NavarroAlex Martinez-MartiDavid MarmolejoAlejandra RezqallahCaterina CarbonellJoan FrigolaRamon AmatAnna PedrolaRodrigo DienstmannEnriqueta FelipNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Susana Cedres Juan-David Assaf Patricia Iranzo Ana Callejo Nuria Pardo Alejandro Navarro Alex Martinez-Marti David Marmolejo Alejandra Rezqallah Caterina Carbonell Joan Frigola Ramon Amat Anna Pedrola Rodrigo Dienstmann Enriqueta Felip Efficacy of chemotherapy for malignant pleural mesothelioma according to histology in a real-world cohort
description	Abstract CheckMate 743 trial demonstrated survival benefit of immunotherapy in first line in MPM with some differences in the efficacy of chemotherapy according to histology. The objective of this study is to characterize the impact of chemotherapy according to histology in patients diagnosed with MPM at our institution. Clinical records of all MPM patients diagnosed at Vall d’Hebron University Hospital between November 2002 and April 2020 were reviewed. Associations between clinical variables and outcomes were assessed with Cox regression models. Survival data were calculated by the Kaplan–Meier method. 189 patients were included with 76% of tumors classified as epithelioid subtype. First line chemotherapy was offered to 85% of patients. Median survival in overall population was 21.3 months (95% CI 17.2–24.3). We found that patients with epithelioid tumors had better overall survival (OS) and progression free survival (PFS). Median OS of epithelioid patients treated with first line chemotherapy was 26.7 months versus 15.0 months in non-epithelioid patients (HR 2.25 CI 95% 1.4–3.4; p < 0.001). Median PFS for patients with epithelioid tumors treated with chemotherapy was 4.8 months versus 3.6 months in non-epithelioid (HR 1.5 CI 95% 1.0–2.3; p = 0.03). The improvement of outcomes in patients with epithelioid histology was detected in patients treated with cisplatin or carboplatin. Histology was not a predictive factor for the platinum agent sensitivity (p of interaction PFS = 0.09, p of interaction OS = 0.65). In our series, patients with non-epithelioid tumors presented worse prognosis. Although epithelioid tumors exposed to cisplatin had higher PFS, histology was not a clear predictor of chemotherapy efficacy.
format	article
author	Susana Cedres Juan-David Assaf Patricia Iranzo Ana Callejo Nuria Pardo Alejandro Navarro Alex Martinez-Marti David Marmolejo Alejandra Rezqallah Caterina Carbonell Joan Frigola Ramon Amat Anna Pedrola Rodrigo Dienstmann Enriqueta Felip
author_facet	Susana Cedres Juan-David Assaf Patricia Iranzo Ana Callejo Nuria Pardo Alejandro Navarro Alex Martinez-Marti David Marmolejo Alejandra Rezqallah Caterina Carbonell Joan Frigola Ramon Amat Anna Pedrola Rodrigo Dienstmann Enriqueta Felip
author_sort	Susana Cedres
title	Efficacy of chemotherapy for malignant pleural mesothelioma according to histology in a real-world cohort
title_short	Efficacy of chemotherapy for malignant pleural mesothelioma according to histology in a real-world cohort
title_full	Efficacy of chemotherapy for malignant pleural mesothelioma according to histology in a real-world cohort
title_fullStr	Efficacy of chemotherapy for malignant pleural mesothelioma according to histology in a real-world cohort
title_full_unstemmed	Efficacy of chemotherapy for malignant pleural mesothelioma according to histology in a real-world cohort
title_sort	efficacy of chemotherapy for malignant pleural mesothelioma according to histology in a real-world cohort
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/dda7bac31e5741c2aadbfeb55a39dc46
work_keys_str_mv	AT susanacedres efficacyofchemotherapyformalignantpleuralmesotheliomaaccordingtohistologyinarealworldcohort AT juandavidassaf efficacyofchemotherapyformalignantpleuralmesotheliomaaccordingtohistologyinarealworldcohort AT patriciairanzo efficacyofchemotherapyformalignantpleuralmesotheliomaaccordingtohistologyinarealworldcohort AT anacallejo efficacyofchemotherapyformalignantpleuralmesotheliomaaccordingtohistologyinarealworldcohort AT nuriapardo efficacyofchemotherapyformalignantpleuralmesotheliomaaccordingtohistologyinarealworldcohort AT alejandronavarro efficacyofchemotherapyformalignantpleuralmesotheliomaaccordingtohistologyinarealworldcohort AT alexmartinezmarti efficacyofchemotherapyformalignantpleuralmesotheliomaaccordingtohistologyinarealworldcohort AT davidmarmolejo efficacyofchemotherapyformalignantpleuralmesotheliomaaccordingtohistologyinarealworldcohort AT alejandrarezqallah efficacyofchemotherapyformalignantpleuralmesotheliomaaccordingtohistologyinarealworldcohort AT caterinacarbonell efficacyofchemotherapyformalignantpleuralmesotheliomaaccordingtohistologyinarealworldcohort AT joanfrigola efficacyofchemotherapyformalignantpleuralmesotheliomaaccordingtohistologyinarealworldcohort AT ramonamat efficacyofchemotherapyformalignantpleuralmesotheliomaaccordingtohistologyinarealworldcohort AT annapedrola efficacyofchemotherapyformalignantpleuralmesotheliomaaccordingtohistologyinarealworldcohort AT rodrigodienstmann efficacyofchemotherapyformalignantpleuralmesotheliomaaccordingtohistologyinarealworldcohort AT enriquetafelip efficacyofchemotherapyformalignantpleuralmesotheliomaaccordingtohistologyinarealworldcohort
_version_	1718442667009900544

Efficacy of chemotherapy for malignant pleural mesothelioma according to histology in a real-world cohort

Ejemplares similares